Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching

Anhua Wei, Lu Zeng, Lu Wang, Lin Gui, Wenting Zhang, Xuepeng Gong, Juan Li, Dong LiuFrontiers in Pharmacology 2023 · DOI

Abstract

Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China; however, limited real-world data exists regarding their effectiveness and safety. Methods: We conducted a retrospective cohort study involving hospitalized COVID-19 patients in China between December 2022 and January 2023. Demographic, clinical, and safety variables were recorded. Results: Among 6,616 hospitalized COVID-19 patients, 725 were included (461 azvudine recipients and 264 nirmatrelvir/ritonavir recipients) after exclusions and 1:2 propensity score matching. No significant difference was found in composite disease progression events (azvudine: 21.26% vs. nirmatrelvir/ritonavir: 27.27%, p = 0.066). However, azvudine was associated with a significant reduction in ICU admission (p = 0.038) and the need for invasive mechanical ventilation (p = 0.035). Safety outcomes were similar between groups (7.16% vs. 8.33%, p = 0.565). Conclusion: Azvudine treatment demonstrated similar safety and slightly better clinical benefits compared to nirmatrelvir/ritonavir in hospitalized COVID-19 patients in a real-world setting.

Introduction

The rapid evolution of the COVID-19 pandemic necessitated the quick deployment of antiviral therapies. While nirmatrelvir/ritonavir (Paxlovid) has gained global recognition, azvudine—a dual-target nucleoside analog developed in China—offers a different therapeutic mechanism. Clinicians often face challenges in choosing between these agents due to a lack of direct head-to-head comparisons, particularly in hospitalized populations. Nirmatrelvir/ritonavir, while effective, is complicated by significant drug-drug interactions. This study addresses this evidence gap by analyzing real-world data from the massive Omicron wave in China (late 2022 to early 2023).

Methods

This retrospective cohort study was conducted at Tongji Hospital in Wuhan, China, utilizing Electronic Medical Records (EMRs) from December 1, 2022, to January 31, 2023. To minimize selection bias inherent in observational data, researchers employed Propensity Score Matching (PSM). Patients were matched based on age, sex, BMI, comorbidities, and disease severity at admission.

Figure 1: Flowchart illustrating the identification and selection process for the azvudine and nirmatrelvir/ritonavir cohorts.

The primary endpoint was a composite of disease progression events, including ICU admission, invasive mechanical ventilation, and in-hospital death.

Results

The initial pool of 6,616 patients was narrowed to a matched cohort of 725 patients (461 azvudine; 264 nirmatrelvir/ritonavir). The matching process successfully balanced baseline characteristics across the two groups.

Figure 2: Baseline demographic and clinical characteristics of the study population before and after propensity score matching.

Clinical Outcomes

While the primary composite outcome did not reach statistical significance (p = 0.066), a trend favoring azvudine was observed. Significant differences were found in secondary outcomes:

  • ICU Admission: Azvudine recipients had lower rates (p = 0.038).
  • Invasive Ventilation: Azvudine significantly reduced the need for ventilation (p = 0.035).
  • In-hospital Death: No significant difference was observed (p = 0.991).

Laboratory markers also indicated that azvudine was associated with a better recovery of renal function (eGFR) compared to the nirmatrelvir/ritonavir group (p = 0.007).

Safety

The safety profiles were comparable. Drug-related adverse events occurred in 7.16% of the azvudine group and 8.33% of the nirmatrelvir/ritonavir group (p = 0.565), suggesting that both drugs are well-tolerated in a hospital setting.

Discussion

The findings suggest that azvudine may offer specific advantages for hospitalized patients, particularly in reducing the burden on intensive care resources. Subgroup analyses hinted at enhanced benefits for patients with diabetes or chronic kidney disease (CKD). Given the dosing complexities of nirmatrelvir/ritonavir in CKD patients, azvudine may serve as a more practical alternative for this high-risk demographic.

However, several limitations must be considered. The retrospective, single-center design may introduce unmeasured confounding. Additionally, the lack of data on vaccination status and the exact timing of symptom onset limits the depth of the analysis.

Conclusion

In this real-world comparison, azvudine demonstrated comparable safety and potentially superior clinical benefits in preventing severe disease progression compared to nirmatrelvir/ritonavir. These results support azvudine as a viable treatment option for hospitalized COVID-19 patients, though large-scale, multi-center randomized controlled trials are needed for definitive confirmation.

Summary updated

Abstract

<b>Background:</b> Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety. <b>Methods:</b> We conducted a retrospective cohort study involving the hospitalized COVID-19 patients in China between December 2022 and January 2023. Demographic, clinical, and safety variables were recorded. <b>Results:</b> Among the 6,616 hospitalized COVID-19 patients, we included a total of 725 patients including azvudine recipients (N = 461) and nirmatrelvir/ritonavir (N = 264) recipients after exclusions and propensity score matching (1:2). There was no significant difference in the composite disease progression events between azvudine (98, 21.26%) and nirmatrelvir/ritonavir (72, 27.27%) groups (<i>p</i> = 0.066). Azvudine was associated with a significant reduction in secondary outcomes, including the percentage of intensive care unit admission (<i>p</i> = 0.038) and the need for invasive mechanical ventilation (<i>p</i> = 0.035), while the in-hospital death event did not significantly differ (<i>p</i> = 0.991). As for safety outcomes, 33 out of 461 patients (7.16%) in azvudine group and 22 out of 264 patients (8.33%) in nirmatrelvir/ritonavir group experienced drug-related adverse events between the day of admission (<i>p</i> = 0.565). <b>Conclusion:</b> In our real-world setting, azvudine treatment demonstrated similar safety compared to nirmatrelvir/ritonavir in hospitalized COVID-19 patients. Additionally, it showed slightly better clinical benefits in this population. However, further confirmation through additional clinical trials is necessary.
BibTeX
@inproceedings{wei2023head,
  author = {Anhua Wei and Lu Zeng and Lu Wang and Lin Gui and Wenting Zhang and Xuepeng Gong and Juan Li and Dong Liu},
  title = {{Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1274294},
}
Figure